Survodutide reduces weight by 9.8% in adults with obesity and type 2 diabetes
- In a phase 3 trial, adults with obesity and type 2 diabetes who received once-weekly survodutide lost significantly more weight than those on placebo.
- The 6.0-mg dose produced a mean weight reduction of 9.8% at week 76, compared with 3.9% for placebo.
- At week 76, the mean weight change was -8.2% (95% CI, -9.2 to -7.2) in the 3.6-mg group and -9.8% (95% CI, -10.8 to -8.8) in the 6.0-mg group, compared with -3.9% (95% CI, -4.9 to -2.9) in the placebo group.
- Weight reduction of at least 5% from baseline occurred in 57.6% of the 3.6-mg group, 64.5% of the 6.0-mg group, and 35.1% of the placebo group, with P<0.001 for all comparisons with placebo.
The publication
In a phase 3 trial, adults with obesity and type 2 diabetes who received once-weekly survodutide lost significantly more weight than those on placebo. The 6.0-mg dose produced a mean weight reduction of 9.8% at week 76, compared with 3.9% for placebo.
Who the findings apply to
The trial included adults with type 2 diabetes and a body-mass index of 27 or higher.
Participants were randomly assigned in a 1:1:1 ratio to receive once-weekly subcutaneous survodutide (3.6 mg or 6.0 mg) or placebo.
The study population had a mean age of 55.7 years and a mean baseline BMI of 36.5, with 49.3% of participants being men.
Why this matters
For people managing both type 2 diabetes and obesity, weight loss is a central therapeutic goal. Survodutide, a dual glucagon and GLP-1 receptor agonist, demonstrated substantial weight reduction and glycated hemoglobin improvements, suggesting it may offer metabolic benefits beyond standard weight management.
What the study found
At week 76, the mean weight change was -8.2% (95% CI, -9.2 to -7.2) in the 3.6-mg group and -9.8% (95% CI, -10.8 to -8.8) in the 6.0-mg group, compared with -3.9% (95% CI, -4.9 to -2.9) in the placebo group.
Weight reduction of at least 5% from baseline occurred in 57.6% of the 3.6-mg group, 64.5% of the 6.0-mg group, and 35.1% of the placebo group, with P<0.001 for all comparisons with placebo.
The mean change in glycated hemoglobin level from a baseline of 7.4% was -0.9 percentage points in the 3.6-mg group, -0.8 percentage points in the 6.0-mg group, and -0.2 percentage points in the placebo group.
What the result does not establish
The most common adverse events were gastrointestinal, occurring in 72.8% of the 3.6-mg group, 77.7% of the 6.0-mg group, and 38.6% of the placebo group; these were generally mild to moderate and transient.
The trial was funded by Boehringer Ingelheim, and the results are based on the treatment-regimen estimand, which assessed effects regardless of whether the trial regimen was discontinued or interrupted or whether other antiobesity therapies were used.
Authors’ conclusion
“In adults with obesity and type 2 diabetes, survodutide at a weekly dose of 3.6 mg or 6.0 mg resulted in significantly greater weight reduction than placebo.”
Trial registration
Registered with the trial registry as NCT06066528. ENCLAI does not hold this registry record, so its details are not shown; follow the link to read it.
Registered with the trial registry as NCT06066528. ENCLAI does not hold this registry record, so its details are not shown; follow the link to read it.
Study and sources
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
Randomised trial · Phase 3 · NEJM · 2026-10-01
Sources and limitations
- PubMed record PMID 42820639 (PubMed / NLM · 2026-10-02)
- Trial registry NCT06066528 (ClinicalTrials.gov · 2026-10-02)
Related briefings
Follow ENCLAI News
Get new briefings in your news reader. No ENCLAI account needed.
The daily disease brief
One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.


